Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT01566240
PHASE3

Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer

Sponsor: University College, London

View on ClinicalTrials.gov

Summary

Chemoradiation has been the standard treatment for advanced cervical cancer for a decade, but one third of women still die from a failure to control systemic disease. In a recent multicentre phase II trial of 46 women the investigators found that, 68% of women had tumours that responded to weekly induction chemotherapy prior to chemoradiation. The induction chemotherapy had acceptable toxicity and did not compromise the standard chemoradiation treatment. In addition, the overall survival and progression free survival at 3 years was 66% (95% CI 4779). These results, together with acceptable toxicity, provide justification for evaluating induction chemotherapy prior to chemoradiation in a randomised phase III trial. The investigators aim to investigate in a randomised trial whether additional induction chemotherapy given on a weekly schedule immediately before standard chemoradiation leads to an improvement in overall survival. The investigators plan to recruit 770 women with locally advanced cervical cancer who are eligible for standard chemoradiation, they will be randomised to weekly carboplatin and paclitaxel chemotherapy for 6 weeks followed by chemoradiation or to chemoradiation alone. The trial will recruit for 4 years with 5 years of follow up period.

Official title: A Phase III Multicentre Trial of Weekly Induction Chemotherapy Followed by Standard Chemoradiation Versus Standard Chemoradiation Alone in Patients With Locally Advanced Cervical Cancer

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

500

Start Date

2012-11-08

Completion Date

2026-12

Last Updated

2024-12-05

Healthy Volunteers

No

Conditions

Interventions

DRUG

Paclitaxel

Paclitaxel 80 mg/m2 (capped at 162mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 \& 36.

DRUG

Carboplatin

Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, \& 36.

RADIATION

Radiotherapy

Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.

DRUG

Cisplatin

Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.

Locations (35)

Instituto do Câncer do Estado de São Paulo

São Paulo, Brazil

Chittaranjan National Cancer Institute (CNCI)

Kolkata, India

Saroj Gupta Cancer Centre and Research Institute

Kolkata, India

Istituto Europeo di Oncologia

Milan, Lombardy, Italy

Instituto Nacional de Cancerologia (INCAN)

Mexico City, Mexico

North Devon District Hospital

Barnstaple, Devon, United Kingdom

University College London Hospital

London, Greater London, United Kingdom

Weston Park Hospital

Sheffield, South Yorkshire, United Kingdom

Belfast City Hospital

Belfast, United Kingdom

Pilgrim Hospital

Boston, United Kingdom

Royal Sussex County Hospital

Brighton, United Kingdom

Velindre Cancer Centre

Cardiff, United Kingdom

Cheltenham General Hospital

Cheltenham, United Kingdom

Royal Derby Hospital

Derby, United Kingdom

Royal Devon and Exeter NHS Foundation Trust

Exeter, United Kingdom

Beatson WOSCC

Glasgow, United Kingdom

Gloucester Royal Hospital

Gloucester, United Kingdom

Grantham and District Hospital

Grantham, United Kingdom

Castle Hill Hospital

Hull, United Kingdom

Leicester Royal Infirmary

Leicester, United Kingdom

Lincoln County Hospital

Lincoln, United Kingdom

Guy's and St Thomas' NHS Foundation Trust

London, United Kingdom

Imperial College Healthcare NHS Trust

London, United Kingdom

St Bart's Hospital

London, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom

The Clatterbridge Cancer Centre

Metropolitan Borough of Wirral, United Kingdom

James Cook University Hospital

Middlesbrough, United Kingdom

Northampton General Hospital

Northampton, United Kingdom

Norfolk and Norwich University Hospital

Norwich, United Kingdom

Nottingham University Hospitals NHS Trust

Nottingham, United Kingdom

Derriford Hospital

Plymouth, United Kingdom

Southampton General Hospital

Southampton, United Kingdom

Royal Stoke University Hospital

Stoke-on-Trent, United Kingdom

Royal Cornwall Hospital

Truro, United Kingdom

New Cross Hospital

Wolverhampton, United Kingdom